Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. reports developments from a clinical-stage biopharmaceutical business focused on miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. News commonly centers on financial results, business updates, manufacturing and clinical-development spending, and progress for semaglutide-based implant candidates such as NPM-139 for chronic weight management and NPM-133 for type 2 diabetes.
The company’s updates also cover Cortigent, its wholly owned subsidiary developing brain implant devices based on precision neurostimulation technology. Cortigent disclosures include the Orion® Visual Cortical Prosthesis System, a cortical stimulation system under development to provide visual perception for blind persons, as well as equity financings, registered direct offerings, private placements, shareholder matters and governance updates.
Vivani Medical, Inc. (NASDAQ: VANI) announced its participation at the ThinkEquity investor conference on October 26, 2022, at 11:00 am EDT in New York. CEO Adam Mendelsohn will provide a company overview, while CFO Brigid Makes will host investor meetings. The presentation will be available live at https://wsw.com/webcast/tep23/vani/1674436, and a replay will be accessible on the company’s website. Vivani focuses on developing long-term therapeutic implants, notably its lead program, NPM-119, aimed at improving adherence to Type 2 diabetes medication.
Vivani Medical, Inc. (NASDAQ: VANI) has announced its trading debut on The Nasdaq Capital Market today following its merger with Nano Precision Medical, Inc. The company holds approximately $55 million in cash, aimed at advancing its product portfolio which includes the NPM-119 (exenatide implant) for Type 2 diabetes. Vivani’s focus is on developing drug and device implants for chronic diseases and visual prostheses for blindness. CEO Adam Mendelsohn expressed optimism about the future of the company and its technologies, particularly the NanoPortal implant technology.
Second Sight Medical Products, Inc. has successfully merged with Nano Precision Medical, Inc., now rebranded as Vivani Medical, Inc., trading under the ticker VANI on Nasdaq. Following the merger, Vivani has approximately $55 million to develop products, including the NPM-119 implant for diabetes treatment and the Orion visual prosthesis for blind patients. The leadership team, led by NPM’s CEO Dr. Adam Mendelsohn, aims to tackle medication non-adherence and advance innovative therapies.